{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:59:48Z","timestamp":1792897188108,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"\n Objective<\/jats:title>\n This study aims to comprehensively evaluate risk factors for denosumab-related osteonecrosis of the jaw (ONJ), focusing on dosage, concomitant medications, and patient demographics, to inform clinical decision-making and optimize therapeutic strategies.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A retrospective pharmacovigilance analysis was conducted using data from the US FDA Adverse Event Reporting System (FAERS) spanning Q2\u20132010 to Q3 2024. Disproportionality analysis, logistic regression analysis, and time-to-onset analysis were employed to assess the association between denosumab use and ONJ. Key variables included dosage (60 mg Q6m\n vs<\/jats:italic>\n . 120 mg Q4w), concomitant medications (e.g., bisphosphonates, glucocorticoids, chemotherapies), and patient demographics (age, sex).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 7,689 denosumab-related ONJ cases, the 120 mg dose demonstrated markedly higher ONJ risk (reporting odds ratio [ROR] = 245.47\n vs<\/jats:italic>\n . 28.59 for 60 mg;\n P<\/jats:italic>\n &lt; 0.001), with a 54-day shorter median onset time (452\n vs<\/jats:italic>\n . 506 days; P = 0.011). Combination therapies synergistically amplified risk, with sequential administration of zoledronic acid yielding the highest ROR at 726.43 (95% CI: 642.83\u2013820.90) and an accelerated time to onset (median 378 days\n vs<\/jats:italic>\n . 462 days for monotherapy). Multivariate logistic regression confirmed age \u226565 years (adjusted odds ratio [aOR] = 1.48), high-dose denosumab (aOR = 7.18), and concomitant medications (e.g., bisphosphonates, glucocorticoids, chemotherapies) as independent risk factors. Male patients had a threefold higher risk than females (ROR = 231.11\n vs<\/jats:italic>\n . 51.01), while age showed minimal influence on latency periods (\n P<\/jats:italic>\n = 0.808). Weibull analysis demonstrated wear-out failure (\u03b2&gt;1) in most subgroups, indicating cumulative toxicity; however, random failure patterns (\u03b2\u22481) were observed with: 60 mg dosing and either sequential therapies (alendronate\/ibandronate\/risedronate) or combination therapy with methotrexate.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study demonstrates that the risk of denosumab-related ONJ is multifactorial, driven by high-dose regimens (120 mg Q4w), specific polypharmacy (particularly concomitant bisphosphonates and glucocorticoids) and male sex. These findings underscore the need for prospective validation and mechanistic investigation into the underlying drug interactions.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fendo.2025.1586626","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:18:00Z","timestamp":1766121480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk factors for denosumab-related osteonecrosis of the jaw: a pharmacovigilance study using the U.S. FDA adverse event reporting system database"],"prefix":"10.3389","volume":"16","author":[{"given":"Hehe","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2017.01.007","article-title":"Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care - cancer care ontario clinical practice guideline","volume":"29","author":"Alibhai","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch Osteoporos"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.42646","article-title":"2022 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-Induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.11005\/jbm.2018.25.4.195","article-title":"Korean guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"25","author":"Park","year":"2018","journal-title":"J Bone Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0196","article-title":"NCCN bone health task force: key recommendations","volume":"12","author":"Farooki","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"B10","doi-asserted-by":"publisher","first-page":"Cd012432","DOI":"10.1002\/14651858.CD012432.pub2","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"10","author":"Beth-Tasdogan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.23324","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1017391","article-title":"Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database","volume":"13","author":"Peng","year":"2022","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/scd.12877","article-title":"Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis","volume":"44","author":"Zhang","year":"2024","journal-title":"Spec Care Dentist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40360-023-00657-y","article-title":"Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"24","author":"Ahdi","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6429","article-title":"A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab","volume":"12","author":"Bracchi","year":"2023","journal-title":"Cancer Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-00385","article-title":"Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: A retrospective cohort study","volume":"38","author":"Kajizono","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-021-04261-4","article-title":"Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab","volume":"26","author":"Wick","year":"2022","journal-title":"Clin Oral Investig"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-022-00324-4","article-title":"Osteonecrosis of the jaw caused by denosumab in treatment-na\u00efve and pre-treatment with zoledronic acid groups: A time-to-onset study using the Japanese adverse drug event report (JADER) database","volume":"9","author":"Hasegawa","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s00520-024-08974-6","article-title":"High-dose denosumab (Xgeva\u00ae) Associated Medication-Related Osteonecrosis of the Jaws (MRONJ): incidence and clinical characteristics in a retrospective analysis of 1278 patients","volume":"32","author":"Moon","year":"2024","journal-title":"Support Care Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2018.02.010","article-title":"Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw","volume":"125","author":"Higuchi","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2461203","article-title":"Associations of acute kidney injury with oral anticoagulants: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database","author":"Bai","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2174\/1574886310666150729112903","article-title":"The role of disproportionality analysis of pharmacovigilance databases in safety regulatory actions: a systematic review","volume":"10","author":"Dias","year":"2015","journal-title":"Curr Drug Saf"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0291658","DOI":"10.1371\/journal.pone.0291658","article-title":"Development and validation of a nomogram for predicting cefoperazone\/sulbactam-induced hypoprothrombinaemia in Hospitalized adult patients","volume":"18","author":"Bai","year":"2023","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b14-00191","article-title":"Analysis of the interaction between clopidogrel, aspirin, and proton pump inhibitors using the FDA adverse event reporting system database","volume":"38","author":"Suzuki","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura","year":"2015","journal-title":"J Pharm Health Care Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-024-02425-9","article-title":"Etiopathogenesis of medication-related osteonecrosis of the jaws: a review","volume":"102","author":"Bassan Marinho Maciel","year":"2024","journal-title":"J Mol Med (Berl)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2017.1348001","article-title":"Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab","volume":"73","author":"Loyson","year":"2018","journal-title":"Acta Clin Belg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper","volume":"136","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0278-2391(03)00328-8","article-title":"Osteonecrosis of the jaws associated with cancer chemotherapy","volume":"61","author":"Wang","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jormas.2022.03.012","article-title":"Possible association of methotrexate use with osteonecrosis of the jaw: Systematic review","volume":"123","author":"Milosavljevi\u0107","year":"2022","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.04.051","article-title":"Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients","volume":"67","author":"Thumbigere-Math","year":"2009","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1586626\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:18:02Z","timestamp":1766121482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1586626\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":37,"alternative-id":["10.3389\/fendo.2025.1586626"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1586626","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"article-number":"1586626"}}